Literature DB >> 11485616

Practical prevention of vaginal and rectal transmission of HIV by adapting the oral defense: use of commercial lubricants.

S Baron1, J Poast, D Nguyen, M W Cloyd.   

Abstract

HIV is transmitted to 6.4 million human beings per year and the majority of these transmissions are sexual. Condoms are highly effective and are recommended as the primary preventive. However, the fact that there are millions of sexual transmissions each year indicates that many people do not use condoms and that additional preventives are needed. The mechanisms of natural prevention of oral transmission by saliva may be adaptable to the susceptible vagina and rectum. The objective of our study was to reduce the sexual transmission of HIV by mimicking saliva's targeting of the transmitting infected leukocytes and any cell-free HIV in seminal fluid. The previously recommended anti-HIV topical microbicide, nonoxynol-9, has not prevented HIV transmission in humans, probably because it causes mucosal irritation and attracts CD4(+) cells. To identify effective preparations that are nonirritating, we studied the anti-HIV activity of commercially available, over-the-counter (OTC) lubricants and vaginal preparations that are judged safest by the U.S. Food and Drug Administration (FDA), and are nonirritating. The effect of OTC preparations on both the production of HIV by infected leukocytes and cell-free HIV suspended in seminal fluid was measured under simulated in vivo conditions. We surveyed 22 OTC vaginal preparations and excluded those with low inhibitory activity and those that were inhibitory but likely to be irritating. Three included preparations are highly active against both HIV-infected leukocytes suspended in seminal fluid and active against cell-free HIV, under in vitro conditions that simulate in vivo conditions. Since the preparations identified here as anti-HIV substances have the advantages of being widely available, inexpensive, acceptable, in the safest U.S. FDA category, and may be used by recipient women or men, they should be tested in clinical trials to help prevent sexual transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485616     DOI: 10.1089/088922201300343672

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Sexual diversity among black men who have sex with men in an inner-city community.

Authors:  Maureen Miller; Malin Serner; Meghan Wagner
Journal:  J Urban Health       Date:  2005-02-28       Impact factor: 3.671

2.  Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro.

Authors:  Othell Begay; Ninochka Jean-Pierre; Ciby J Abraham; Anne Chudolij; Samantha Seidor; Aixa Rodriguez; Brian E Ford; Marcus Henderson; David Katz; Thomas Zydowsky; Melissa Robbiani; José A Fernández-Romero
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-08       Impact factor: 2.205

3.  Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.

Authors:  Charlene S Dezzutti; Elizabeth R Brown; Bernard Moncla; Julie Russo; Marilyn Cost; Lin Wang; Kevin Uranker; Ratiya P Kunjara Na Ayudhya; Kara Pryke; Jim Pickett; Marc-André Leblanc; Lisa C Rohan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges.

Authors:  Jim A Turpin
Journal:  Drug Deliv Transl Res       Date:  2011-05-21       Impact factor: 4.617

5.  Pathogenesis of oral FIV infection.

Authors:  Craig Miller; Karen Boegler; Scott Carver; Martha MacMillan; Helle Bielefeldt-Ohmann; Sue VandeWoude
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

6.  Repeated rectal application of a hyperosmolar lubricant is associated with microbiota shifts but does not affect PrEP drug concentrations: results from a randomized trial in men who have sex with men.

Authors:  Richard E Haaland; Jeffrey Fountain; Yingtian Hu; Angela Holder; Chuong Dinh; LaShonda Hall; Nicole A Pescatore; Sheila Heeke; Clyde E Hart; Jiahui Xu; Yi-Juan Hu; Colleen F Kelley
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.